<DOC>
	<DOCNO>NCT00810953</DOCNO>
	<brief_summary>The purpose study investigate safety possible efficacy use pentamidine treatment pancreatic cancer metastasis subject receive standard therapy .</brief_summary>
	<brief_title>A Safety Study Using Pentamidine Patients With Pancreatic Cancer Undergoing Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Histologically cytologically proven diagnosis advance pancreatic adenocarcinoma unresectable metastatic . At least one unidimensionally measurable lesion ( spiral CT scan ) 18 year age old ECOG performance status 0 , 1 2 Serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) £ 2.5 x upper limit normal ( ULN ) , AST ALT £ 5 x ULN liver function abnormality due underlie malignancy Total serum bilirubin £ 2 x ULN lipase within normal limit ( 1.5x ULN ) Absolute neutrophil count ( ANC ) ≥ 1500/uL ( 1.5 x 109/L ) Platelets ≥ 100,000/uL Hemoglobin ≥ 9.0 g/dL Serum creatinine £ 1.5 x ULN calculate creatinine clearance ≥ 50 ml/min CA199 level ≥ 37 U/ml Normal ECG Signed date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial prior enrolment Willingness ability comply schedule visit , treatment plan , laboratory test , trial procedure Life expectancy , opinion investigator , &gt; 3 month BP &lt; 100 ( systolic ) History uncontrolled renal disease , pancreatitis , diabetes mellitus Peripheral sensory neuropathy ( &gt; Grade 1 , per NCI CTCAE version 3.0 ) Concomitant therapy investigational agent participation another clinical trial within previous 3 month . Any following condition : Ongoing cardiac dysrhythmias NCI CTCAE grade ≥ 2 ; atrial fibrillation grade ; QTc interval &gt; 450 msec male &gt; 470 msec female uncontrolled intercurrent illness , e.g. , unstable angina ; severe coronary disease , ventricular arrhythmia , bradycardia &lt; 50 bpm Active uncontrolled bacterial infection Concurrent use drug could prolong QT interval Concurrent use nephrotoxic drug , include aminoglycosides , ampho B , foscarnet , cidofovir Concurrent use drug may associate pancreatitis Concurrent active cancer originate primary site pancreas history cancer &lt; 3 year except skin superficial bladder , uterus etc History allergy hypersensitivity pentamidine Pregnancy breastfeeding . All female patient reproductive potential must negative pregnancy test ( serum urine ) prior first dose study medication . Severe acute chronic medical psychiatric condition , laboratory abnormality would impart , judgement investigator , excess risk associate trial participation study drug administration , judgement investigator , would make subject inappropriate entry trial . On oral anticoagulant ( LMWH acceptable )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>